Sesen Bio, Inc. (SESN) News
Filter SESN News Items
SESN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SESN News Highlights
- SESN's 30 day story count now stands at 8.
- Over the past 16 days, the trend for SESN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BIO, IR and TOP are the most mentioned tickers in articles about SESN.
Latest SESN News From Around the Web
Below are the latest news stories about SESEN BIO INC that investors may wish to consider to help them evaluate SESN as an investment opportunity.
Sesen Bio Stockholders Approve Merger with Carisma TherapeuticsCAMBRIDGE, Mass., March 02, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company’s Special Meeting of Stockholders (the "Special Meeting") held earlier today. |
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsCAMBRIDGE, Mass., February 28, 2023--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update. |
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaCAMBRIDGE, Mass., February 21, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company’s upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. |
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote "FOR" All Proposals at March 2 Special MeetingCAMBRIDGE, Mass., February 16, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company’s upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. ISS is widely recognized as a leading independent proxy advisory firm, providing impartial analys |
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerCAMBRIDGE, Mass., February 16, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. ("Carisma") management team on Tuesday, February 21, 2023, at 8:00 am ET. The discussion will cover Sesen Bio’s pending merger with Carisma, as well as Carisma’s corporate strategy and clinical programs. Sesen Bio stockholders can submit questions in advance to [email protected]. |
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsCAMBRIDGE, Mass., February 15, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announced that BML Investment Partners, L.P. ("BML"), one of Sesen Bio’s top stockholders, intends to vote all of its shares in support of the Company’s pending merger with Carisma Therapeutics Inc. ("Carisma"). |
5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapInvesting.com -- Here is your daily Pro Recap of the biggest dividend headlines you may have missed on InvestingPro since yesterday. Start your free 7-day trial to get this news first. |
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerCAMBRIDGE, Mass. & PHILADELPHIA, February 14, 2023--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement (the "Support Agreement") with Bradley L. Radoff and Michael Torok (together with their respective affiliates, the "Investor Group"). The Investor Group, which beneficially |
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agoMany investors define successful investing as beating the market average over the long term. But in any portfolio... |
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerCAMBRIDGE, Mass., February 02, 2023--Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. ("Carisma"). The presentation can be found at www.SesenBioandCarisma.com. |